Thomas N Darling

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4866537/publications.pdf

Version: 2024-02-01

115 papers	7,930 citations	71102 41 h-index	51608 86 g-index
117 all docs	117 docs citations	117 times ranked	7677 citing authors

#	Article	IF	Citations
1	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 243-254.	2.1	1,185
2	A Mosaic Activating Mutation inAKT1Associated with the Proteus Syndrome. New England Journal of Medicine, 2011, 365, 611-619.	27.0	800
3	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 2013, 49, 255-265.	2.1	693
4	Birt-Hogg-DubÃ© Syndrome. Archives of Dermatology, 1999, 135, 1195-202.	1.4	325
5	Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nature Genetics, 2012, 44, 928-933.	21.4	269
6	Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens. Nature Protocols, 2017, 12, 439-451.	12.0	253
7	Clinical delineation and natural history of the PIK3CAâ€related overgrowth spectrum. American Journal of Medical Genetics, Part A, 2014, 164, 1713-1733.	1.2	249
8	Multiple Facial Angiofibromas and Collagenomas in Patients With Multiple Endocrine Neoplasia Type 1. Archives of Dermatology, 1997, 133, 853.	1.4	241
9	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology, 2021, 123, 50-66.	2.1	230
10	Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet, The, 2001, 357, 1850-1851.	13.7	214
11	Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2016, 172, 402-421.	1.6	195
12	Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17462-17467.	7.1	184
13	Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum. Genetics in Medicine, 2019, 21, 1189-1198.	2.4	115
14	Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway. Dermatologic Clinics, 2017, 35, 51-60.	1.7	111
15	Clinical differentiation between proteus syndrome and hemihyperplasia: Description of a distinct form of hemihyperplasia. , 1998, 79, 311-318.		97
16	Dermatologic and Dental Aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements. JAMA Dermatology, 2014, 150, 1095.	4.1	93
17	Anti-Epiligrin Cicatricial Pemphigoid. Medicine (United States), 2003, 82, 177-186.	1.0	92
18	Cutaneous Manifestations of Proteus Syndrome. Archives of Dermatology, 2004, 140, 947-53.	1.4	81

#	Article	IF	Citations
19	Cutaneous Tumors in Patients with Multiple Endocrine Neoplasia Type 1 Show Allelic Deletion of the MEN1 Gene. Journal of Investigative Dermatology, 1998, 110, 438-440.	0.7	80
20	Mucosal Morbidity in Patients With Epidermolysis Bullosa Acquisita. Archives of Dermatology, 1999, 135, 954-9.	1.4	79
21	Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Human Molecular Genetics, 2014, 23, 2023-2029.	2.9	77
22	Alteration of Skin Properties with Autologous Dermal Fibroblasts. International Journal of Molecular Sciences, 2014, 15, 8407-8427.	4.1	72
23	Oral findings in 58 adults with tuberous sclerosis complex. Journal of the American Academy of Dermatology, 2007, 56, 786-790.	1.2	71
24	A Homozygous Deletion Mutation in the Gene Encoding the 180-kDa Bullous Pemphigoid Antigen (BPAG2) in a Family with Generalized Atrophic Benign Epidermolysis Bullosa. Journal of Investigative Dermatology, 1996, 106, 771-774.	0.7	64
25	Phenotypic Characterization of Disseminated Cells with TSC2 Loss of Heterozygosity in Patients with Lymphangioleiomyomatosis. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1410-1418.	5.6	64
26	Revertant mosaicism: partial correction of a germ-line mutation in COL17A1 by a frame-restoring mutation. Journal of Clinical Investigation, 1999, 103, 1371-1377.	8.2	64
27	Recognition of Tuberous Sclerosis in Adult Women: Delayed Presentation With Life-Threatening Consequences. Annals of Internal Medicine, 2011, 154, 806.	3.9	59
28	TSC2 Loss in Lymphangioleiomyomatosis Cells Correlated with Expression of CD44v6, a Molecular Determinant of Metastasis. Cancer Research, 2007, 67, 10573-10581.	0.9	58
29	CT of Sclerotic Bone Lesions: Imaging Features Differentiating Tuberous Sclerosis Complex with Lymphangioleiomyomatosis from Sporadic Lymphangioleiomymatosis. Radiology, 2010, 254, 851-857.	7.3	57
30	Dissociated Human Dermal Papilla Cells Induce Hair Follicle Neogenesis in Grafted Dermalâ€“Epidermal Composites. Journal of Investigative Dermatology, 2014, 134, 538-540.	0.7	57
31	Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome. American Journal of Human Genetics, 2019, 104, 484-491.	6.2	56
32	Acral lesions in tuberous sclerosis complex: Insights into pathogenesis. Journal of the American Academy of Dermatology, 2010, 63, 244-251.	1.2	54
33	Lymphangioleiomyomatosis (LAM): Molecular insights lead to targeted therapies. Respiratory Medicine, 2010, 104, S45-S58.	2.9	50
34	Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation. Journal of Clinical Investigation, 2016, 127, 349-364.	8.2	49
35	Mesenchymalâ€“epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3539-3544.	7.1	48
36	Premature Termination Codons Are Present on Both Alleles of the Bullous Pemphigoid Antigen 2/Type XVII Collagen Gene in Five Austrian Families with Generalized Atrophic Benign Epidermolysis Bullosa. Journal of Investigative Dermatology, 1997, 108, 463-468.	0.7	47

#	Article	IF	Citations
37	Evolution of skin lesions in Proteus syndrome. Journal of the American Academy of Dermatology, 2005, 52, 834-838.	1.2	47
38	Rapid Shape Change and Release of Ninhydrin-Positive Substances byLeishmania majorPromastigotes in Response to Hypo-Osnjotic Stress. Journal of Protozoology, 1990, 37, 493-499.	0.8	45
39	MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development. Journal of Experimental Medicine, 2005, 202, 617-624.	8.5	44
40	De Novo Biosynthetic Profiling of High Abundance Proteins in Cystic Fibrosis Lung Epithelial Cells. Molecular and Cellular Proteomics, 2006, 5, 1628-1637.	3.8	44
41	Protein microarray platforms for clinical proteomics. Proteomics - Clinical Applications, 2007, 1, 934-952.	1.6	44
42	d-lactate production by Leishmania braziliensis through the glyoxalase pathway. Molecular and Biochemical Parasitology, 1988, 28, 121-127.	1.1	43
43	Progressive overgrowth of the cerebriform connective tissue nevus in patients with Proteus syndrome. Journal of the American Academy of Dermatology, 2010, 63, 799-804.	1.2	43
44	Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus. Journal of the American Academy of Dermatology, 2015, 73, 802-808.	1.2	43
45	Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. Pediatric Neurology, 2016, 60, 1-12.	2.1	43
46	High frequency of <scp>PTEN</scp> mutations in nevi and melanomas from xeroderma pigmentosum patients. Pigment Cell and Melanoma Research, 2014, 27, 454-464.	3.3	40
47	Sirolimus Decreases Circulating Lymphangioleiomyomatosis Cells in Patients With Lymphangioleiomyomatosis. Chest, 2014, 145, 108-112.	0.8	39
48	Carbon dioxide abolishes the reverse Pasteur effect in Leishmania major promastigotes. Molecular and Biochemical Parasitology, 1989, 33, 191-202.	1.1	37
49	Lymphatic Involvement in Lymphangioleiomyomatosis. Annals of the New York Academy of Sciences, 2008, 1131, 206-214.	3.8	36
50	Human TSC2-null fibroblast-like cells induce hair follicle neogenesis and hamartoma morphogenesis. Nature Communications, 2011, 2, 235.	12.8	36
51	Rapidly growing collagenomas in multiple endocrine neoplasia type I. Journal of the American Academy of Dermatology, 2007, 56, 877-880.	1.2	35
52	Bone marrowâ€“derived keratinocytes are not detected in normal skin and only rarely detected in wounded skin in two different murine models. Experimental Hematology, 2006, 34, 672-679.	0.4	33
53	Prevalence of Tuberous Sclerosis Complex in Taiwan: A National Population-Based Study. Neuroepidemiology, 2009, 33, 335-341.	2.3	32
54	Phenotypic distinctions between mosaic forms of tuberous sclerosis complex. Genetics in Medicine, 2019, 21, 2594-2604.	2.4	32

#	Article	IF	Citations
55	A comparative study of d-lactate, l-lactate and glycerol formation by four species of Leishmania and by Trypanosoma lewisi and Trypanosoma brucei gambiense. Molecular and Biochemical Parasitology, 1988, 30, 253-257.	1.1	31
56	Somatic Mutations of the MEN1 Tumor Suppressor Gene Detected in Sporadic Angiofibromas. Journal of Investigative Dermatology, 1998, 111, 539-540.	0.7	31
57	Simultaneous Deficiency in CD28 and STAT6 Results in Chronic Ectoparasite-Induced Inflammatory Skin Disease. Infection and Immunity, 2004, 72, 3706-3715.	2.2	30
58	Human Pluripotent Stem Cellâ€“Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis. Cancer Research, 2017, 77, 5491-5502.	0.9	29
59	Title is missing!. Medicine (United States), 2003, 82, 177-186.	1.0	27
60	Lymphangioleiomyomatosis andTSC2^{-/-}Cells. Lymphatic Research and Biology, 2010, 8, 59-69.	1.1	26
61	AKT1 Gene Mutation Levels Are Correlated with the Type of Dermatologic Lesions in Patients with Proteus Syndrome. Journal of Investigative Dermatology, 2014, 134, 543-546.	0.7	25
62	A Child With Antibodies Targeting Both Linear IgA Bullous Dermatosis and Bullous Pemphigoid Antigens. Archives of Dermatology, 1995, 131, 1438.	1.4	23
63	Cycloheximide Facilitates the Identification of Aberrant Transcripts Resulting from a Novel Splice-Site Mutation in COL17A1 in a Patient with Generalized Atrophic Benign Epidermolysis Bullosa. Journal of Investigative Dermatology, 1998, 110, 165-169.	0.7	22
64	Fibrous cephalic plaques in tuberous sclerosis complex. Journal of the American Academy of Dermatology, 2018, 78, 717-724.	1.2	22
65	The future of academic dermatology in the United States: Report on the resident retreat for future physician-scientists, June 15-17, 2001. Journal of the American Academy of Dermatology, 2002, 47, 300-303.	1.2	21
66	Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models. European Respiratory Review, 2013, 22, 302-311.	7.1	21
67	A model system to analyse the ability of human keratinocytes to form hair follicles. Experimental Dermatology, 2014, 23, 443-446.	2.9	20
68	Accelerated senescence in skin in a murine model of radiation-induced multi-organ injury. Journal of Radiation Research, 2017, 58, 636-646.	1.6	19
69	Treatment of Mycobacterium haemophilum infection with an antibiotic regimen including clarithromycin. British Journal of Dermatology, 1994, 131, 376-379.	1.5	18
70	Clinical Characteristics of Connective Tissue Nevi in Tuberous Sclerosis Complex With Special Emphasis on Shagreen Patches. JAMA Dermatology, 2017, 153, 660.	4.1	18
71	The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 678-683.	2.9	18
72	Recurrent, Activating Variants in the Receptor Tyrosine Kinase DDR2 Cause Warburg-Cinotti Syndrome. American Journal of Human Genetics, 2018, 103, 976-983.	6.2	17

#	Article	IF	Citations
73	Cytokeratin 75 expression in central, centrifugal, cicatricial alopecia â€“ new observations in normal and diseased hair follicles. Journal of Cutaneous Pathology, 2010, 37, 243-248.	1.3	16
74	Effect of beta-agonists on LAM progression and treatment. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E944-E953.	7.1	16
75	A Deletion Mutation in COL17A1 in Five Austrian Families with Generalized Atrophic Benign Epidermolysis Bullosa Represents Propagation of an Ancestral Allele. Journal of Investigative Dermatology, 1998, 110, 170-173.	0.7	15
76	Histologic variants of periungual fibromas in tuberous sclerosis complex. Journal of the American Academy of Dermatology, 2011, 64, 442-444.	1.2	15
77	Cytokeratin 15 expression in central, centrifugal, cicatricial alopecia: new observations in normal and diseased hair follicles. Journal of Cutaneous Pathology, 2011, 38, 407-414.	1.3	14
78	Pathogenetic insights from quantification of the cerebriform connective tissue nevus in Proteus syndrome. Journal of the American Academy of Dermatology, 2018, 78, 725-732.	1.2	14
79	Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 300, L64-L72.	2.9	13
80	Tsc2 disruption in mesenchymal progenitors results in tumors with vascular anomalies overexpressing Lgals3. ELife, 2017, 6, .	6.0	13
81	A diagnostic and management algorithm for individuals with an isolated skin finding suggestive of tuberous sclerosis complex. British Journal of Dermatology, 2017, 176, 220-223.	1.5	12
82	Topical Sirolimus to Treat Tuberous Sclerosis Complex (TSC). JAMA Dermatology, 2018, 154, 761.	4.1	11
83	Hamartomas and tubers from defects in hamartin-tuberin. Journal of the American Academy of Dermatology, 2004, 51, 9-11.	1.2	9
84	Nipple Angiofibromas with Loss of TSC2 Are Associated with Tuberous Sclerosis Complex. Journal of Investigative Dermatology, 2016, 136, 535-538.	0.7	9
85	Birt-Hogg-DubÃ© syndrome initially diagnosed as tuberous sclerosis complex. JAAD Case Reports, 2019, 5, 368-371.	0.8	9
86	Circulating Lymphangioleiomyomatosis Tumor Cells With Loss of Heterozygosity in the TSC2 Gene Show Increased Aldehyde Dehydrogenase Activity. Chest, 2019, 156, 298-307.	0.8	8
87	Comprehensive analysis of gene expression profiles in keratinocytes from patients with generalized atrophic benign epidermolysis bullosa. Experimental Dermatology, 2002, 11, 75-81.	2.9	7
88	Hitting the Mark in Hamartoma Syndromes. Advances in Dermatology, 2006, 22, 181-200.	2.0	7
89	The Adult Phenotype of Tuberous Sclerosis Complex. Acta Dermato-Venereologica, 2016, 96, 278-280.	1.3	7
90	Antibody Microarrays: Analysis of Cystic Fibrosis. Methods in Molecular Biology, 2012, 823, 179-200.	0.9	7

#	Article	IF	Citations
91	Apparent Sporadic Lymphangioleiomyomatosis (LAM) in a Man Due to Extreme Mosaicism for a TSC2 Mutation. Annals of the American Thoracic Society, 2017, 14, 1227-1229.	3.2	6
92	Ultrasensitive profiling of UV-induced mutations identifies thousands of subclinical facial tumors in tuberous sclerosis complex. Journal of Clinical Investigation, 2022, 132, .	8.2	6
93	A diagnostic algorithm for enhanced detection of mosaic tuberous sclerosis complex in adults. British Journal of Dermatology, 2020, 182, 235-237.	1.5	5
94	Generalised mosaicism for TSC2 mutation in isolated lymphangioleiomyomatosis. European Respiratory Journal, 2019, 54, 1900938.	6.7	5
95	Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice. JCI Insight, 2021, 6, .	5.0	5
96	Hypertrichotic patches as a mosaic manifestation of Proteus syndrome. Journal of the American Academy of Dermatology, 2021, 84, 415-424.	1.2	4
97	Miliary fibromas in tuberous sclerosis complex. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1226-1229.	2.4	4
98	Molecular heterogeneity of the cerebriform connective tissue nevus in mosaic overgrowth syndromes. Journal of Physical Education and Sports Management, 2019, 5, a004036.	1.2	3
99	Histopathological features of fibrous cephalic plaques in tuberous sclerosis complex. Histopathology, 2021, 79, 619-628.	2.9	3
100	A Mixed Blood-Lymphatic Endothelial Cell Phenotype in Lymphangioleiomyomatosis and Idiopathic Pulmonary Fibrosis but Not in Kaposiâ€™s Sarcoma or Tuberous Sclerosis Complex. American Journal of Respiratory Cell and Molecular Biology, 2022, 66, 337-340.	2.9	3
101	Effects of anaerobiosis on adenine nucleotide levels and the release of ATP by Leishmania major promastigotes. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1989, 94, 453-460.	0.2	2
102	Hair graying may occur early in life in tuberous sclerosis complex and is distinct from poliosis. Journal of the American Academy of Dermatology, 2021, 84, 788-790.	1.2	2
103	Dermatologic findings in individuals with genetically confirmed Proteus syndrome. Pediatric Dermatology, 2021, 38, 794-799.	0.9	2
104	Central centrifugal cicatricial alopecia: A common but underâ€recognized and underâ€treated disease finally comes of age. Journal of Cutaneous Pathology, 2022, 49, 204-206.	1.3	2
105	Identification of Disseminated CD44v6+/CD9+Cells withTSC2Loss of Heterozygosity in Patients with Lymphangioleiomyomatosis.. , 2009, , .		1
106	Dermatological adverse events associated with use of oral mechanistic target of rapamycin inhibitors in a cohort of individuals with tuberous sclerosis complex. British Journal of Dermatology, 2020, 183, 588-589.	1.5	1
107	TSC1 and TSC2 Genotype in Tuberous Sclerosis Complex: Are Other Manifestations of this Multisystem Disease Affected by Genotype?. Annals of the American Thoracic Society, 2021, 18, 775-777.	3.2	1
108	Long-Term Effects of Sirolimus on Human Skin TSC2-Null Fibroblastâ€Like Cells. Journal of Investigative Dermatology, 2021, 141, 2291-2299.e2.	0.7	1

#	Article	IF	Citations
109	Physical, Psychological and Ethical issues in Caring for Individuals with Genetic Skin Disease. Journal of Nursing Scholarship, 2013, 45, 89-95.	2.4	0
110	Acne following Blaschko's lines in Proteus syndrome. JAAD Case Reports, 2020, 6, 1072-1074.	0.8	0
111	Mosaic forms of an autosomal dominant skin disorder. British Journal of Dermatology, 2020, 183, 14-15.	1.5	0
112	Eruptive collagenomas associated with adalimumab treatment of juvenile rheumatoid arthritis. Journal of Cutaneous Pathology, 2020, 47, 197-201.	1.3	0
113	Pathophysiology of Lymphangioleiomyomatosis. Respiratory Medicine, 2021, , 101-120.	0.1	0
114	Progression of skin lesions in Warburg-Cinotti syndrome. JAAD Case Reports, 2022, 20, 47-49.	0.8	0
115	<scp>Lateâ€onset</scp> Proteus syndrome with cerebriform connective tissue nevus and subsequent development of intraductal papilloma. American Journal of Medical Genetics, Part A, 2022, , .	1.2	0